ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of Omeprazole Effect on Glaucoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01000220
Recruitment Status : Unknown
Verified October 2009 by Shahid Beheshti University of Medical Sciences.
Recruitment status was:  Recruiting
First Posted : October 22, 2009
Last Update Posted : May 4, 2010
Sponsor:
Collaborator:
Ophthalmic Research Center
Information provided by:
Shahid Beheshti University of Medical Sciences

Brief Summary:
Omeprazole is a safe drug listed in OTC drug due to its safety. It acts by irreversible inhibition of K/H ATP ase pump and also Na/K ATP ase, Na/H ATP ase.Considering these actions the effect of omeprazole on decreasing intra ocular pressure is an issue of debate.In this Randomized Clinical Trial conducted in labafinejad hospital, patients with glaucoma who need to take omeprazole due to GI problem are evaluated in two groups including placebo and drug users. The effect will be finally assessed.

Condition or disease Intervention/treatment Phase
Glaucoma Drug: Omeprazole Drug: Placebo Phase 1

Detailed Description:
Omeprazole is a safe drug listed in OTC drug due to its safety. It acts by irreversible inhibition of K/H ATP ase pump and also Na/K ATP ase, Na/H ATP ase.Considering these actions the effect of omeprazole on decreasing intra ocular pressure is an issue of debate.In this Randomized Clinical Trial conducted in labafinejad hospital, patients with glaucoma who need to take omeprazole due to GI problem are evaluated in two groups including placebo and drug users. The effect will be finally assessed.

Study Type : Interventional  (Clinical Trial)
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Evaluation of Omeprazole Effect on Glaucoma

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Glaucoma
U.S. FDA Resources

Arm Intervention/treatment
Active Comparator: Omeprazole Drug: Omeprazole
Placebo Comparator: placebo Drug: Placebo




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • patients with glaucoma
  • 18 to 70 years
  • POAG patients, Pseudoexfoliation
  • no history of other systemic disease
  • no history of intraocular intervention
  • no history of H2 blocker or PPI consumption during the past month consuming 2 or less topical anti-glaucoma medication
  • no present immune deficiency
  • no addiction habit

Exclusion Criteria:


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01000220


Contacts
Contact: Yazdani Shahin, MD +982122585952 labbafi@hotmail.com

Locations
Iran, Islamic Republic of
Ophthalmic Research Center Recruiting
Tehran, Iran, Islamic Republic of, 166666
Contact: Shahin yazdani, MD    +98 21 22585952    labbafi@hotmail.com   
Sponsors and Collaborators
Shahid Beheshti University of Medical Sciences
Ophthalmic Research Center

Responsible Party: Ophthalmic Research Center
ClinicalTrials.gov Identifier: NCT01000220     History of Changes
Other Study ID Numbers: 8735
First Posted: October 22, 2009    Key Record Dates
Last Update Posted: May 4, 2010
Last Verified: October 2009

Additional relevant MeSH terms:
Glaucoma
Ocular Hypertension
Eye Diseases
Omeprazole
Anti-Ulcer Agents
Gastrointestinal Agents
Proton Pump Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action